Raptor Set To Fly As Commercial Company With Procysbi Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Procysbi was approved by FDA April 30 for the ultra-rare disease nephropathic cystinosis and will be priced in line with other orphan drugs at an average annual cost per patient of $250,000.